Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension.

Trial Profile

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Netarsudil (Primary) ; Timolol
  • Indications Glaucoma; Ocular hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms Rocket 4
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2017 According to an Aerie Pharmaceuticals media release, a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled with the company for October 13, 2017 to review the NDA for Rhopressa (netarsudil ophthalmic solution) 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
    • 12 Apr 2017 Status changed from active, no longer recruiting to completed, according to an Aerie Pharmaceuticals media release.
    • 12 Apr 2017 According to an Aerie Pharmaceuticals media release, this study will provide six-month safety data adequate for regulatory filing in Europe and is not required for U.S. FDA approval. The European regulatory filing for Rhopressa is currently expected to take place in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top